Patents by Inventor Antonio Gualberto

Antonio Gualberto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10760130
    Abstract: Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 1, 2020
    Assignee: MOLECULAR TEMPLATES, INC.
    Inventors: Brian A. Elenbaas, Antonio Gualberto, Charles Praray Hart
  • Publication number: 20200246325
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Application
    Filed: August 7, 2018
    Publication date: August 6, 2020
    Inventor: Antonio Gualberto
  • Publication number: 20200191793
    Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 18, 2020
    Applicants: Janssen Diagnostics, LLC, Pfizer Inc.
    Inventors: Antonio GUALBERTO, Maria Luisa PACCAGNELLA, Carrie L. MELVIN, Madeline I. REPOLLET, David CHIANESE, Mark Carle CONNELLY, Leonardus Wendelinus Mathias Marie TERSTAPPEN
  • Publication number: 20200000795
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: February 21, 2018
    Publication date: January 2, 2020
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20200000796
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: August 14, 2019
    Publication date: January 2, 2020
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10471055
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 12, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10426767
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: October 1, 2019
    Assignee: Kura Oncolofy, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10335404
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 2, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10292979
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 21, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20190119758
    Abstract: The present invention relates to the field of molecular biology, cell biology, and cancer biology. Specifically, the present invention relates to methods of treating peripheral T-cell lymphoma (“PTCL”) with a famesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the PTCL subtypes and additional characteristics.
    Type: Application
    Filed: April 21, 2017
    Publication date: April 25, 2019
    Inventor: Antonio Gualberto
  • Publication number: 20190060303
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: April 5, 2018
    Publication date: February 28, 2019
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20190038617
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Application
    Filed: November 21, 2017
    Publication date: February 7, 2019
    Inventor: Antonio GUALBERTO
  • Patent number: 10137121
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 27, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20180334716
    Abstract: Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 22, 2018
    Inventors: Brian A. Elenbaas, Antonio Gualberto, Charles Praray Hart
  • Publication number: 20180280376
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20180235952
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 23, 2018
    Inventors: Antonio GUALBERTO, Catherine Rose Scholz
  • Patent number: 10022364
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20180193329
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 12, 2018
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Publication number: 20180187266
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Application
    Filed: November 2, 2017
    Publication date: July 5, 2018
    Applicant: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 9956215
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 1, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz